Hot TopicIf there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example
Introduction
Taxanes are approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in metastatic and early breast cancer. Despite registration, it was concluded in the most recent Cochrane review that there was no evidence of a survival benefit in metastatic breast cancer for single-agent taxanes versus anthracyclines.1 And, although an overall survival benefit was seen in favour of taxane containing regimens, the superiority of taxane regimens over non-taxane containing regimens was not seen if the non-taxane regimens were largely limited to optimally-dosed anthracycline-based regimens.1 In a second review on taxanes in metastatic breast cancer, it was concluded that single-agent taxane was even less effective than single-agent anthracycline, based on the EORTC study 10923.2 On the other hand, it was concluded that first-line anthracycline–taxane combinations seemed slightly better than anthracycline-based regimens with regard to tumor response and progression-free survival, although not with regard to overall survival. However, the conclusions from meta-analyses on adjuvant taxane breast cancer trials were remarkably different, showing an improvement in both disease-free and overall survival.[3], [4], [5]
In recent years, new drugs have shown activity in metastatic breast cancer, but not always resulting in an overall survival benefit.6 In the oncology community this has led to discussions on whether such drugs should be reimbursed. A thorough analysis of drugs without a clear survival gain in metastatic breast cancer but with a survival gain in early breast cancer may help clarify this apparent discrepancy, and may prevent premature conclusions on the value of new drugs in this field. For that reason, we decided to systematically review taxane-based chemotherapy studies in early and metastatic breast cancer, to assess which factors may have caused the different outcomes between these patient groups.
Section snippets
Search strategy and selection criteria
A detailed search strategy, consisting of numerous MeSH heading and text word combinations, “breast cancer”, “chemotherapy”, “taxanes”, “docetaxel” and “paclitaxel”, was used to search the PubMed database. Publications of clinical phase III trials between 1995 and November 1, 2010 in the English language were included. Abstracts of the annual meetings of the American Society of Clinical Oncology (ASCO) and of the San Antonio Breast Cancer Symposium (SABCS) were searched for relevant trials (and
Overall efficacy of taxanes in metastatic and early breast cancer
In total 10 trials in the metastatic breast cancer setting were included, comparing taxane containing chemotherapy schemes with anthracycline containing schemes (Table 1). We calculated the pooled hazard ratio and found no significant difference for progression-free survival with a hazard ratio of 0.94 (95% CI 0.88–1.01) and for overall survival with a hazard ratio of 0.98 (95% CI 0.91–1.05) (Fig. A, Appendix).
In total 21 trials in the adjuvant breast cancer setting were included, comparing
Discussion
In our meta-analysis, we included 10 randomized trials that assessed the role of taxanes in the metastatic breast cancer setting, and 21 trials in the early breast cancer setting. We show that the use of taxanes did not improve overall survival in metastatic breast cancer trials (hazard ratio of 0.98; 95% CI 0.91–1.05), whereas it did so in early breast cancer (hazard ratio of 0.85; 95% CI 0.79–0.91). The primary goal of our review and meta-analysis was to determine whether the study design
Conflicts of interest statement
The authors indicated no potential conflicts of interest.
Funding
Netherlands Organization for Health Research and Development (ZonMw 80-82500-98-10901).
References (54)
- et al.
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
(2010) - et al.
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial
Ann Oncol
(2010) - et al.
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Lancet
(2009) - et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Ann Oncol
(2005) - et al.
Epirubicin: is it like doxorubicin in breast cancer? A clinical review
Breast
(2012) - et al.
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer
Ann Oncol
(2001) - et al.
Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel
Eur J Cancer
(2011) - et al.
Taxane containing regimens for metastatic breast cancer
Cochrane Database Syst Rev
(2005) - et al.
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
J Clin Oncol
(2008) - et al.
Taxanes for adjuvant treatment of early breast cancer
Cochrane Database Syst Rev
(2007)
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients
Cancer
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
J Clin Oncol
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
J Clin Oncol
Practical methods for incorporating summary time-to-event data into meta-analysis
Trials
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer
J Natl Cancer Inst
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)
J Clin Oncol
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
J Clin Oncol
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over
J Clin Oncol
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial
J Clin Oncol
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial
J Clin Oncol
Multicentric phase III study in first line treatment of advanced metastatic breast cancer. Epirubicin/Paclitaxel (ET) vs Epirubicin/Cyclophosphamide (EC). A study of the Ago breast cancer group
J Clin Oncol
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
J Clin Oncol
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre
J Clin Oncol
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial
Onkologie
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group phase III study
J Clin Oncol
Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735
J Clin Oncol
Adjuvant docetaxel for node-positive breast cancer
N Engl J Med
Cited by (0)
- d
Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands. Tel.: +31 43 3877025; fax: +31 43 3876281.
- e
Department of Internal Medicine, Maxima Medisch Centrum, P.O. Box 90052, 5600 PD Eindhoven, The Netherlands. Tel.: +31 40 8885320; fax: +31 43 3876281.
- f
Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Tel.: +31 (0) 43 3882387; fax: +31 43 3876281.